• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Isoray To Announce Third Quarter Fiscal 2022 Financial Results on May 10, 2022

    4/29/22 8:05:00 AM ET
    $ISR
    Medical Specialities
    Health Care
    Get the next $ISR alert in real time by email

    RICHLAND, Wash., April 29, 2022 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the third quarter fiscal 2022 ended March 31, 2022 on Tuesday, May 10, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the third quarter fiscal year 2022 after the close of the U.S. stock markets on Tuesday, May 10, 2022.

    To listen to the conference call, please dial (888) 506-0062. For callers outside the U.S., please dial (973) 528-0011.

    The conference call will be simultaneously webcast and can be accessed at https://www.webcaster4.com/Webcast/Page/2199/45391. The webcast will be available until August 10, 2022 following the conference call.

    About Isoray

    Isoray, Inc. is a medical technology company pioneering advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers throughout the body. Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Follow us on LinkedIn and Twitter.



    Contact
    Investor Relations: Mark Levin (501) 255-1910
    Media and Public Relations: Sharon Schultz (302) 539-3747

    Primary Logo

    Get the next $ISR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISR

    DatePrice TargetRatingAnalyst
    9/14/2021$1.25Outperform
    Northland Capital Markets
    More analyst ratings

    $ISR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Initial Results From First Patient Dosed With Perspective Therapeutics' Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session

    RICHLAND, Wash. & CORALVILLE, Iowa, Feb. 22, 2023 (GLOBE NEWSWIRE) --  Perspective, Therapeutics, Inc. (formerly known as "Isoray, Inc.") (NYSE:CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the presentation of extremely encouraging results regarding 212Pb-VMT-α-NET, its lead preclinical candidate for neuroendocrine tumors (NET), currently being used therapeutically in India on a compassionate use basis. Dr Vikas Prasad presented the results at the 2023 PET Radiotracer Translation and Resource Center (PET-RTRC) Work

    2/22/23 5:02:57 PM ET
    $CATX
    $ISR
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

    RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE:ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three months ended December 31, 2022. "The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company's core brachytherapy business lack of orders from our largest customer and post-COVID recovery

    2/16/23 4:05:02 PM ET
    $ISR
    Medical Specialities
    Health Care

    Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

    Company's focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy and its newly merged partner Viewpoint Molecular Targeting, Inc., today announced that they are now doing business as Perspective Therapeutics, Inc., along with a new brand identity effective immediately. Isoray, Inc. will change its name to Perspective Therapeutics, Inc. by filing an amendment to its

    2/7/23 5:48:04 PM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Williamson Robert F Iii bought $90,710 worth of shares (127,206 units at $0.71), increasing direct ownership by 60% to 338,761 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    2/1/24 4:53:13 PM ET
    $ISR
    Medical Specialities
    Health Care

    Williamson Robert F Iii bought $78,474 worth of shares (135,879 units at $0.58), increasing direct ownership by 180% to 211,555 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    1/30/24 4:57:17 PM ET
    $ISR
    Medical Specialities
    Health Care

    Puhlmann Markus bought $139,888 worth of shares (280,000 units at $0.50), increasing direct ownership by 26% to 1,375,425 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    1/26/24 5:40:04 PM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Williamson Robert F Iii bought $90,710 worth of shares (127,206 units at $0.71), increasing direct ownership by 60% to 338,761 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    2/1/24 4:53:13 PM ET
    $ISR
    Medical Specialities
    Health Care

    Williamson Robert F Iii bought $78,474 worth of shares (135,879 units at $0.58), increasing direct ownership by 180% to 211,555 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    1/30/24 4:57:17 PM ET
    $ISR
    Medical Specialities
    Health Care

    Puhlmann Markus bought $139,888 worth of shares (280,000 units at $0.50), increasing direct ownership by 26% to 1,375,425 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    1/26/24 5:40:04 PM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    SEC Filings

    View All

    IsoRay Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    2/5/24 4:34:33 PM ET
    $ISR
    Medical Specialities
    Health Care

    SEC Form D filed by IsoRay Inc.

    D - Perspective Therapeutics, Inc. (0000728387) (Filer)

    1/22/24 4:17:28 PM ET
    $ISR
    Medical Specialities
    Health Care

    IsoRay Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    1/22/24 4:10:45 PM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital Markets initiated coverage on Isoray with a new price target

    Northland Capital Markets initiated coverage of Isoray with a rating of Outperform and set a new price target of $1.25

    9/14/21 8:21:18 AM ET
    $ISR
    Medical Specialities
    Health Care

    Lake Street initiated coverage on IsoRay with a new price target

    Lake Street initiated coverage of IsoRay with a rating of Buy and set a new price target of $3.00

    2/18/21 8:47:05 AM ET
    $ISR
    Medical Specialities
    Health Care

    HC Wainwright & Co. reiterated coverage on Isoray with a new price target

    HC Wainwright & Co. reiterated coverage of Isoray with a rating of Buy and set a new price target of $2.10 from $1.25 previously

    2/10/21 6:11:10 AM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Leadership Updates

    Live Leadership Updates

    View All

    Isoray Announces the Appointment of Donna Fort as Vice President Sales and Marketing

    RICHLAND, Wash., April 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed Vice President, Sales and Marketing. CEO Lori Woods said Fort's appointment adds key expertise. "I am very excited to welcome Donna to the Isoray team. Donna brings some twenty-five years of experience in driving increased company revenue and in building and leading sales and marketing teams. Donna also brings a keen understanding of radiation therapy sequencing, and combination therapy with oncologic agents including immunotherapy to her role at Isoray." Woods concluded, "We believe Donna's proven d

    4/13/21 8:13:00 AM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Financials

    Live finance-specific insights

    View All

    Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

    RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE:ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three months ended December 31, 2022. "The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company's core brachytherapy business lack of orders from our largest customer and post-COVID recovery

    2/16/23 4:05:02 PM ET
    $ISR
    Medical Specialities
    Health Care

    Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

    RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2023 ended September 30, 2022 and provided updates regarding the pending merger with Viewpoint Molecular Targeting. Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company. "The pending merger represents an exciting transformational opportunity for Isoray and all our stakeholders. It provides us with the opportunity to build on Isoray's existing business with a pipeline of very

    11/10/22 4:05:00 PM ET
    $ISR
    Medical Specialities
    Health Care

    Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

    RICHLAND, Wash., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2023 ended September 30, 2022 on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the first quarter fiscal year 2023 after the close of the U.S. stock markets on November 10, 2022. To listen to the conference call, please dial (877) 545-0320. For callers outside the U.S., please dial (973) 528-0002

    10/31/22 8:14:00 AM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IsoRay Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    9/18/23 9:20:56 PM ET
    $ISR
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by IsoRay Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    9/18/23 8:02:56 PM ET
    $ISR
    Medical Specialities
    Health Care